Last month1 we focused on children’s health worldwide, and in May we focused on women’s health. This month we will focus on men’s health .
According to this WHO bulletin titled,
The men’s health gap:
men must be included in the global health equity agenda
several issues are of note:
- Women are outliving men by an average of almost 6 years
- Eastern Europe showed the biggest difference in life expectancy where women in the Russian Federation were outliving men by an average of 11.6 years
- Upon reviewing the social determinants of health, factors impacting men’s poorer survival rates include:
- greater levels of occupational exposure to physical and chemical hazards
- health behavior paradigms related to masculinity , such as reduced compliance with regular checkups and follow up care for known conditions
- men are less likely to visit a doctor when they are ill and, when they see a doctor, are less likely to report on the symptoms of disease or illness
The study highlighted in this WHO bulletin concluded that men’s physical illness, for example, can impair the psychological health of their female partners; when men are sick, injured or die, households and female partners suffer a loss of income. Closing the men’s health gap can benefit men, women and their children.
Did you know?
- Cancer-causing viral infections such as HBV/HCV and HPV are responsible for up to 20% of cancer deaths in low- and middle-income countries
- More than 60% of the world’s new annual cancer cases occur in Africa, Asia and Central and South America
CTK’s Men’s Health Related Tests
Non-invasive test to screen for prostate cancer or monitor patients in remission.
An immunochemical assay designed specifically to detect trace amounts of human fecal occult blood which can indicate early stage colorectal cancer. CTK’s tests offers many advantages over the commonly-used but inferior
- highly sensitive and specific with clear, easy-to-read results
- no dietary restrictions
- only 1 specimen required, 2 recommended
- Positivia external FOB assay controls are available to ensure laboratory compliance.
CTK offers two simple accurate cost effective methods to aid in management of H. pylori infection
- H. pylori Ab Combo rapid test (Catalog # R0191C) detects antibodies in blood specimens for an initial screening of H. pylori infection history.
- H. pylori Ag Rapid Test (Catalog # R0192C) detects H. pylori antigen shed in feces as an indication of active infection or effectiveness of treatment.
- H. pylori Rapid Tests utilize reagents developed in-house at CTK’s ISO:13485, QMS certified facilities to ensure test quality, delivery time, and cost effectiveness.